Suppr超能文献

台湾念珠菌属、新型隐球菌及曲霉菌属临床分离株的抗真菌药敏性:2003年台湾多中心抗菌药物耐药性监测计划数据

Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.

作者信息

Hsueh Po-Ren, Lau Yeu-Jun, Chuang Yin-Ching, Wan Jen-Hsien, Huang Wen-Kuei, Shyr Jainn-Ming, Yan Jing-Jou, Yu Kwok-Woon, Wu Jiunn-Jong, Ko Wen-Chien, Yang Yi-Chueh, Liu Yung-Ching, Teng Lee-Jene, Liu Cheng-Yi, Luh Kwen-Tay

机构信息

Department of Laboratory Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Rd., Taipei 100, Taiwan.

出版信息

Antimicrob Agents Chemother. 2005 Feb;49(2):512-7. doi: 10.1128/AAC.49.2.512-517.2005.

Abstract

The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 microg/ml, and for all other Candida species isolates, voriconazole MICs were </=0.5 microg/ml. The proportions of isolates for which amphotericin B MICs were >/=2 microg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were >/=16 microg/ml, and two (3%) isolates were not inhibited by 1 mug of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 microg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 microg/ml) and 90% (2 microg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by </=1 microg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

摘要

对来自台湾七家不同医院的391株七种念珠菌属的血液分离株、70株新型隐球菌临床分离株(来自血液或脑脊液)以及96株四种曲霉菌临床分离株(作为台湾多中心抗菌药物耐药性监测研究组2003年项目的一部分),测定了非重复分离株对六种抗真菌药物的敏感性。除光滑念珠菌和克柔念珠菌外,所有念珠菌属分离株对氟康唑敏感。在59株光滑念珠菌分离株中,16株(27%)对氟康唑不敏感,且所有菌株对伊曲康唑呈剂量依赖性敏感或耐药。对于3株(5.1%)光滑念珠菌分离株,伏立康唑的最低抑菌浓度(MIC)为2至4μg/ml,而对于所有其他念珠菌属分离株,伏立康唑的MIC≤0.5μg/ml。两性霉素B的MIC≥2μg/ml的分离株比例,克柔念珠菌为100%(3株),白色念珠菌为11%(207株中的23株),热带念珠菌为3.0%(67株中的2株),光滑念珠菌为20%(59株中的12株),近平滑念珠菌和葡萄牙念珠菌均为0%。对于3株(4%)新型隐球菌分离株,氟康唑的MIC≥16μg/ml,2株(3%)分离株不受1μg/ml两性霉素B的抑制。对于4株(4.2%)曲霉菌分离株,伊曲康唑的MIC为8μg/ml。黄曲霉对两性霉素B的敏感性较低,其使50%(1μg/ml)和90%(2μg/ml)的分离株受到抑制的MIC比烟曲霉和黑曲霉高两倍。所有曲霉菌分离株均被≤1μg/ml的伏立康唑抑制,包括对两性霉素B和伊曲康唑耐药性增加的分离株。本研究揭示了台湾地区念珠菌属对两性霉素B的敏感性降低以及新型隐球菌对氟康唑和两性霉素B的敏感性降低的情况。伏立康唑是针对所测试的真菌分离株最有效的药物,包括对氟康唑和两性霉素B不敏感的菌株。

相似文献

2
Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Diagn Microbiol Infect Dis. 2008 Jun;61(2):175-80. doi: 10.1016/j.diagmicrobio.2008.01.011. Epub 2008 Mar 4.
4
In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia.
Enferm Infecc Microbiol Clin. 2009 Nov;27(9):518-22. doi: 10.1016/j.eimc.2008.09.013. Epub 2009 May 23.
7
Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Diagn Microbiol Infect Dis. 2005 Mar;51(3):179-83. doi: 10.1016/j.diagmicrobio.2004.11.004.

引用本文的文献

1
The antidepressant drug sertraline is a novel inhibitor of yeast Pah1 and human lipin 1 phosphatidic acid phosphatases.
J Lipid Res. 2025 Jan;66(1):100711. doi: 10.1016/j.jlr.2024.100711. Epub 2024 Nov 20.
2
Understanding the environmental drivers of clinical azole resistance in species.
Drug Target Insights. 2022 Nov 22;16:25-35. doi: 10.33393/dti.2022.2476. eCollection 2022 Jan-Dec.
4
Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.
J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):6-22. doi: 10.1089/jop.2018.0089. Epub 2018 Nov 8.
6
Triazole Resistance in Aspergillus spp.: A Worldwide Problem?
J Fungi (Basel). 2016 Jul 4;2(3):21. doi: 10.3390/jof2030021.
7
Triazole Resistance in Aspergillus Species: An Emerging Problem.
Drugs. 2017 Apr;77(6):599-613. doi: 10.1007/s40265-017-0714-4.

本文引用的文献

2
Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals.
Antimicrob Agents Chemother. 2004 Apr;48(4):1197-203. doi: 10.1128/AAC.48.4.1197-1203.2004.
3
The role of antifungal susceptibility testing in the therapy of candidiasis.
Diagn Microbiol Infect Dis. 2004 Mar;48(3):153-60. doi: 10.1016/j.diagmicrobio.2003.10.003.
4
In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
Diagn Microbiol Infect Dis. 2004 Feb;48(2):101-5. doi: 10.1016/j.diagmicrobio.2003.09.009.
5
Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
J Antimicrob Chemother. 2004 Mar;53(3):526-9. doi: 10.1093/jac/dkh106. Epub 2004 Feb 12.
6
Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):33-7. doi: 10.1016/j.diagmicrobio.2003.08.002.
8
Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
J Med Microbiol. 2004 Feb;53(Pt 2):129-134. doi: 10.1099/jmm.0.05326-0.
9
Guidelines for treatment of candidiasis.
Clin Infect Dis. 2004 Jan 15;38(2):161-89. doi: 10.1086/380796. Epub 2003 Dec 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验